Celldex Therapeutics (NASDAQ: CLDX) — Perfil da empresa, notícias e dados financeiros
Cathay General Bancorp offers diverse financial services, aiming for sustainable growth and top-tier solutions for clients.

Celldex Therapeutics
Celldex Therapeutics (NASDAQ:CLDX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer and other difficult-to-treat diseases. Drawing on a deep expertise in immunology, Celldex is pioneering a robust pipeline of potential therapies designed to enhance the body's natural defenses against disease. The company's projects span from early-stage research to phase 3 clinical trials, with key focuses on precision medicine and immune therapeutics. Through strategic collaborations and cutting-edge research, Celldex aims to improve patient outcomes and advance the field of medicine. Their objective is not only to deliver life-changing treatments to patients in need but also to lead the way in discovering and developing new pathways for treating cancer and immune-related diseases.
Resumo
Operações
Produtos e/ou serviços de Celldex Therapeutics
- CDX-0159: A monoclonal antibody targeting KIT for chronic inducible urticaria, currently in Phase 2 clinical trials.
- CDX-1140: An immune activating agonist targeting CD40, involved in Phase 1 trials for solid tumors and B-cell malignancies.
- CDX-527: A combination of an anti-PD-L1 and an anti-CD27 in one molecule, designed for various cancers, in Phase 1 trials.
- Glembatumumab vedotin: An antibody-drug conjugate targeting gpNMB for advanced melanoma and breast cancer, previously in clinical trials.
- Varlilumab: An agonist antibody targeting CD27 to activate the immune system against cancer, involved in clinical research.
- CDX-301: A recombinant human Flt3 ligand aimed at enhancing stem cell and immune restoration, used in various clinical settings.
equipe executiva do Celldex Therapeutics
- Anthony S. MarucciFounder, President, CEO & Director
- Tibor KelerFounder, Chief Scientific Officer & Executive VP
- Sam MartinSenior VP, CFO, Secretary & Treasurer
- Elizabeth CrowleyChief Product Development Officer & Senior VP
- Margo Heath-ChiozziSenior Vice President of Regulatory Affairs
- Joseph P. SchlessingerCo-Founder & Member of Scientific Advisory Board
- Sarah CavanaughSenior Vice President of Corporate Affairs & Administration
- Freddy A. JimenezSenior VP & General Counsel
- Ronald A. PepinChief Business Officer & Senior VP
- Diane C. YoungSenior VP & Chief Medical Officer
Últimas notícias sobre a Celldex Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Celldex Therapeutics, em USD.
- Cap. de mercado
- 2,3 bi
- Receita (TTM)
- 158 mil
- P/L
- —
- LPA (diluído, TTM)
- -4.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1,5 mi | -287,4 mi | -258,8 mi | |
| 7 mi | -195,1 mi | -157,9 mi | |
| 6,9 mi | -154,5 mi | -141,4 mi | |
| 2,4 mi | -115,2 mi | -112,3 mi |